The pet joint health supplement market is projected to grow from USD 2,100 million in 2025 to USD 3,763.3 million by 2035, expanding at a CAGR of 6.0%. By pet type, dogs will remain the dominant pet type with a 78% share, while glucosamine will lead the active-ingredient category with 24% share.